Background: Hypoxic–ischemic brain injury triggers persistent microglial hyperactivation, which drives progressive secondary neuroinflammation and subsequent neurological deficits. Nicotinamide mononucleotide (NMN), a key nicotinamide adenine dinucleotide (NAD+) precursor, confers neuroprotective effects in neonatal hypoxic–ischemic injury models. Nevertheless, the molecular landscape linking NMN treatment to metabolic and inflammatory reprogramming in microglia remains incompletely characterized. Methods: Primary mouse microglia were subjected to oxygen–glucose deprivation/reoxygenation (OGD/R) insult. Three experimental groups were established: a Control, OGD/R, and OGD/R + NMN. We combined mitochondrial ultrastructural and functional assessments, DESeq2-based transcriptomic profiling for unbiased molecular screening, followed by RT-qPCR and supernatant-based ELISA for target-oriented validation. Results: OGD/R exposure induced severe mitochondrial structural damage, intracellular depletion of NAD+ and ATP, and excessive reactive oxygen species (ROS) generation; these pathological phenotypes were partially attenuated by NMN supplementation. Transcriptomic profiling identified co-regulated gene subsets in which OGD/R-dependent expression alterations showed opposing changes after NMN intervention. Transcriptomic analysis pinpointed two core molecular signatures: the Nlrp3-Casp1 inflammasome cascade and lipid-droplet-associated molecular markers, including Hilpda and Plin2. Multi-level molecular validation demonstrated that NMN treatment was associated with reduced transcript levels of Nlrp3, Casp1, Hilpda, and Plin2, accompanied by reduced secretion of mature IL-1β and TNF-α. Conclusions: Collectively, this correlative transcriptomic study shows that NMN treatment correlates with mitigation of OGD/R-provoked pro-inflammatory remodeling in microglia, alongside partial restoration of mitochondrial homeostasis and attenuated transcript levels of NLRP3 inflammasome and lipid-droplet-associated markers. These findings identify NMN-associated molecular responses that warrant further mechanistic investigation and in vivo validation under hypoxic–ischemic brain-injury conditions. Genetic manipulation and in vivo animal experiments are essential before drawing any therapeutic conclusions.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: